A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled 15 charts
Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML
Phase 2 Completed
42 enrolled 9 charts
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
Phase 2 Completed
273 enrolled
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Phase 2 Completed
75 enrolled 14 charts
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
Phase 2 Completed
56 enrolled 11 charts
CHA
Phase 2 Completed
65 enrolled
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
200 enrolled
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Phase 2 Completed
68 enrolled 13 charts
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Phase 2 Completed
24 enrolled 9 charts
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Phase 2 Completed
57 enrolled 13 charts
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
Phase 2 Completed
60 enrolled 9 charts
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
Phase 2 Completed
55 enrolled 12 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
PEVENAZA
Phase 2 Completed
164 enrolled 12 charts
CLARA
Phase 2 Completed
735 enrolled
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Phase 2 Completed
80 enrolled 56 charts
A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Phase 2 Completed
114 enrolled
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
PTCyRuxo
Phase 2 Completed
128 enrolled
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Phase 2 Completed
12 enrolled
INCB018424 in Patients With Advanced Hematologic Malignancies
Phase 2 Completed
51 enrolled 8 charts
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
150 enrolled 17 charts
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Phase 2 Completed
84 enrolled
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Phase 2 Completed
20 enrolled
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2 Completed
78 enrolled 16 charts
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Phase 2 Completed
38 enrolled
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Phase 2 Completed
28 enrolled 10 charts
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Phase 2 Completed
46 enrolled
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Phase 2 Completed
21 enrolled 14 charts
VITAL
Phase 2 Completed
42 enrolled 12 charts
PONALLO
Phase 2 Completed
23 enrolled
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Phase 2 Completed
67 enrolled 21 charts
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Phase 2 Completed
33 enrolled 7 charts
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Phase 2 Completed
16 enrolled 13 charts
Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma
Phase 2 Completed
38 enrolled
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Completed
155 enrolled 24 charts
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Phase 2 Completed
98 enrolled 17 charts
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Phase 2 Completed
22 enrolled 8 charts
Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
30 enrolled
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Phase 2 Completed
63 enrolled
CPX-351 TA-SMP
Phase 2 Completed
42 enrolled
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Phase 2 Completed
112 enrolled
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Phase 2 Completed
7 enrolled 12 charts
PTBCy
Phase 2 Completed
50 enrolled
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Phase 2 Completed
111 enrolled 71 charts
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
Phase 2 Completed
38 enrolled 14 charts
Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Phase 2 Completed
42 enrolled 19 charts